MBX Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Microbix Biosystems (TSE: MBX)
›
Microbix Biosystems (TSE: MBX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.2950 CAD on 19 November 2026, up 18.0% over 52 weeks. Its 52-week range is 0.2100 CAD to 0.3200 CAD: the price is 7.8% below the high and 40.5% above the low.
Its market capitalisation is 40.41M CAD.
Microbix Biosystems reports return on equity of -8.1%, an operating margin of -27.8% and revenue up 16.9% year over year.
It holds more cash than debt, a net cash position of 440.07K CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 0.4000 CAD is 35.6% above the current price. The next earnings report is expected on 17 December 2026.